Harvey Alter

Harvey Alter is an American physician and medical researcher noted for his pivotal role in identifying transfusion-associated hepatitis later shown to be primarily caused by the Hepatitis C virus. His work at National Institutes of Health transformed blood safety, linking clinical observation, laboratory investigation, and public health action to reduce post-transfusion morbidity and mortality. Alter’s studies influenced policies at the Food and Drug Administration and testing practices at blood centers such as the American Red Cross.

Early life and education

Alter was born in New York City and attended Columbia University for undergraduate studies before earning his medical degree at New York University School of Medicine. During postgraduate training he completed residency and clinical rotations that included service at institutions connected to Beth Israel Hospital (Manhattan), exposure to transfusion medicine at academic centers, and affiliation with federal research programs at the National Institutes of Health. His early mentors included investigators from Mount Sinai Hospital and clinicians affiliated with the American College of Physicians who influenced his focus on clinical infectious disease and hematology.

Medical career and research

Alter spent most of his career at the National Institutes of Health’s Clinical Center (NIH) and later in laboratories tied to the Division of Viral Hepatitis at the Centers for Disease Control and Prevention. He led systematic studies of post-transfusion liver disease, collaborating with hematologists, virologists, epidemiologists, and transfusion services including the American Red Cross and hospital blood banks. Alter’s multidisciplinary teams employed clinical cohorts from Georgetown University Hospital and laboratory partnerships with groups at Rockefeller University and University of California, San Francisco to develop serological assays and biochemical markers. His work intersected with investigators at Merck and academic virology groups including those at Columbia University Irving Medical Center and contributed to regulatory guidance from the Food and Drug Administration.

Discovery of non-A, non-B hepatitis and hepatitis C virus

In the 1970s and early 1980s, Alter and colleagues documented cases of chronic hepatitis following transfusion that were not explained by known agents such as Hepatitis A virus or Hepatitis B virus. Through large-scale surveillance of transfusion recipients, epidemiologic linkage studies with the American Red Cross blood donor archives, and biochemical characterization, Alter provided compelling evidence for an infectious agent he termed "non-A, non-B hepatitis." These findings guided molecular virologists including teams at Chiron Corporation and researchers at Centers for Disease Control and Prevention and Scripps Research in isolating viral genomes, leading to the identification of the Hepatitis C virus by scientists such as Michael Houghton and collaborators. The subsequent development and implementation of nucleic acid testing and serologic screening targeted at hepatitis C dramatically reduced transfusion-transmitted hepatitis worldwide, influencing public health recommendations from the World Health Organization and national blood services in countries like United Kingdom and Australia.

Awards and honors

Alter received numerous recognitions for his contributions to medicine and public health, including the Lasker Award and the Nobel Prize in Physiology or Medicine. He has been elected to professional bodies such as the National Academy of Medicine and honored by organizations including the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Academic institutions such as Yale University and Harvard Medical School have conferred honorary degrees and named lectureships, and Alter’s publications earned him lifetime achievement awards from transfusion societies like the International Society of Blood Transfusion.

Personal life and legacy

Alter’s career exemplifies the translation of clinical observation into public health intervention, linking work at the National Institutes of Health and collaborations with entities such as the American Red Cross, Centers for Disease Control and Prevention, and private biotech firms to reduce infectious risk in blood products. His mentorship influenced generations of hepatologists and virologists at institutions including University of Pennsylvania, Johns Hopkins University, and Stanford University School of Medicine. Alter’s legacy endures in blood screening policies, hepatitis C elimination efforts endorsed by the World Health Organization, and in the continued research programs at the National Institutes of Health and allied academic centers.

Category:American physicians Category:1935 births